Although endocrine therapy using selective estrogen receptor modulators (SERMs), such as Fulvestrant, has improved treatment outcomes for estrogen receptor-positive (ER+) breast cancer, drug resistance and tumor recurrence remain significant challenges. Here, ESR1 is linked to neoplasm.